FDA updated Safety Communication: Ondansetron (Zofran) 32-mg, single IV dose pulled due to potential for serious cardiac risks

News
Article

The 32-mg, single intravenous (IV) dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed because of the potential for serious cardiac risk, according to an updated Safety Communication from FDA.

Newsletter

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Recent Videos
Related Content
© 2025 MJH Life Sciences

All rights reserved.